Menu

Report Library

All Reports
HER2+ Breast Cancer KOL Interview - UK

September 20, 2023

A UK-based KOL provides insights into prescribing habits, key marketed brands, and late-phase pipeline therapies for HER2+ breast cancer. Key pipeline assets highlighted include Enhertu, Tecentriq, Piqray, and Tukysa. 

This interview was conducted on 25 July 2023. 

If you are a KOL Insight Subscriber, please access the interview from our KOL Insight portal (Subscribers only). 

Biomedtracker's KOL Insight transcripts are available through subscription only. For more information on obtaining a KOL Insight subscription, please email Biomedtracker or call Biomedtracker Client Services at (888) 670-8900.

For our disclosures, please read the Biomedtracker Research Standards.

Indications Covered: HER2+ Breast Cancer

 Additional Resources: